Kiniksa Pharmaceuticals
KNSA
105 hedge funds and large institutions have $538M invested in Kiniksa Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 33 increasing their positions, 38 reducing their positions, and 21 closing their positions.
2% more capital invested
Capital invested by funds: $526M → $538M (+$11.6M)
3% less funds holding
Funds holding: 108 → 105 (-3)
3.1% less ownership
Funds ownership: 94.09% → 91% (-3.1%)
13% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 38
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
22% less call options, than puts
Call options by funds: $5.1M | Put options by funds: $6.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.92M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.18M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$7.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.45M |
| 5 |
Millennium Management
New York
|
+$4.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$20.5M |
| 2 |
Barclays
London,
United Kingdom
|
-$8.7M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$6.89M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.85M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$5.22M |
KNSA Hedge Fund Activity: Q1 2021 in Review
105 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2021, worth a combined $538M — up 2.2% from $526M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of KNSA and 18 opened new positions — a net loss of 3 holders — while 38 trimmed existing stakes and 33 added.
The largest buyer was Pictet Asset Management (UK), adding an estimated $8.92M. The largest seller was Ameriprise, cutting an estimated $20.5M.
- 105 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2021, down from 108 in Q4 2020.
- Funds reported $538M of Kiniksa Pharmaceuticals stock for Q1 2021, up 2.2% quarter-over-quarter.
- 18 funds opened new Kiniksa Pharmaceuticals positions in Q1 2021 and 21 closed out, a net change of -3 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2021 was Pictet Asset Management (UK), an estimated $8.92M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2021 was Ameriprise, an estimated $20.5M sold.
Based on aggregated 13F filings for Q1 2021.